查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947952

PrEP药物市场依产品类型、给药途径、通路及作用机制划分，全球预测，2026-2032年

Drugs for PrEP Market by Product Type, Administration Route, Distribution Channel, Mechanism Of Action - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，预防性暴露前 (PrEP) 药物市值将达到 23.4 亿美元，到 2026 年将增长至 25.1 亿美元，复合年增长率为 8.26%，到 ​​2032 年将达到 40.8 亿美元。

关键市场统计数据
基准年 2025 23.4亿美元
预计年份：2026年 25.1亿美元
预测年份 2032 40.8亿美元
复合年增长率 (%) 8.26%

本文将介绍一个充满活力的PrEP预防环境，该环境旨在将临床创新与获取和交付的实际情况相结合。

由于治疗方法创新、医疗服务模式转变以及支付方和政策环境的变化，爱滋病毒暴露前预防（PrEP）领域正经历快速变革。近期临床进展扩大了高风险族群可选择的方案，同时医疗系统和社区服务提供者也在调整服务路径，以提高药物利用率和病患依从性。在此背景下，相关人员必须权衡长效製剂的优势与常规口服疗法的既有作用，以确保临床获益能够转化为实际可及性和公平的结果。

临床创新、不断发展的医疗服务模式以及支付方政策如何融合，共同推动PrEP生态系统的变革

过去几年发生的变革性变化正在重塑暴露前预防（PrEP）的研发、实施和资金筹措方式。最显着的是，长效注射剂的出现挑战了传统口服药物的优势，因为它能提高用药依从性，并带来新的服务提供机会。随着越来越多的证据表明注射剂在不同人群中的有效性，临床医生和医疗系统正在重新思考支持定期就诊、注射给药和监测的护理模式，这反过来又影响着服务提供地点的经济效益和人力资源规划。同时，监管部门的核准和指南的更新正在扩大适应症范围，并为风险分层提供新的见解，迫使支付方重新评估药物清单和事先核准框架。

评估2025年美国关税调整对PrEP供应链和支付方趋势的累积营运和取得影响

2025年实施的累积关税调整引入了新的经济变量，影响PrEP产品的供应链设计、采购选择和定价策略。进口原料药、製剂和包装组件的关税提高，将增加品牌药和非专利生产商的到岸成本，尤其是那些依赖跨境原料采购的供应链。为此，生产商和契约製造生产商正在评估近岸外包、垂直整合和替代筹资策略，以保护利润率并维持供应可靠性。同时，采购部门正在重新考虑供应商多元化，以降低集中风险。

深入的细分洞察，详细阐述产品类型、给药途径、最终用户、分销管道和作用机制如何共同影响策略选择。

对PrEP市场进行细分，可以揭示临床、商业性和营运方面的差异，这些差异应指南策略规划。从产品类型来看，市场由品牌产品（例如长效卡博特韦和已上市的口服组合药物）和学名药（主要是TDF/FTC）组成，两者在临床特征、专利过渡和定价动态方面均存在差异。这些差异会影响生产规模、产品系列部署顺序和患者覆盖范围等方面的决策，因为品牌长效药物可以建立高端定位，而学名药有可能扩大患者的可及性。

从区域观点分析获取和使用情况，揭示了系统和资金筹措不同的暴露前预防（PrEP）推广策略。

区域趋势显着影响暴露前预防（PrEP）介入措施的推广途径和实施重点。儘管美洲拥有成熟的法规环境和完善的预防项目，但取得途径仍有差异。支付方合作和全面护理模式推动了都市区的推广，而地方社区计画对于涵盖边缘化人群至关重要。政策变化、采购框架和本地生产能力进一步加剧了该地区各国应对措施的差异。

关键的竞争考察和伙伴关係洞察凸显了品牌差异化、学名药和分销合作关係将如何影响现实世界中PrEP的覆盖范围和普及程度。

PrEP领域的竞争格局呈现出现有品牌所有者、创新产品参与企业和不断壮大的非专利药生产商之间的平衡。销售长效製剂的品牌所有者已在临床开发和医护人员培训方面投入巨资，以支持诊所内的给药；而销售口服复方製剂的公司则强调便利性、患者援助计划和广泛的药房分销。学名药药生产商在提高药物的可负担性和可及性方面发挥着至关重要的作用，尤其是在那些采购机制优先考虑成本控制和批量采购的地区。

为产业领导者提供切实可行的建议，以确保供应韧性、优化交付并加速公平取得PrEP创新产品。

为了巩固预防成果，产业和政策领导者必须将洞见转化为具体行动。首先，投资多元化供应链和关键材料的双重采购将有助于降低贸易政策波动带来的风险，并确保供应的连续性。其次，产品开发必须与实际供应情况相符。製造商在设计临床方案和包装时，应考虑在医疗机构和社区环境中的便利性，并开发能够满足不同终端使用者需求的依从性支援措施。

一种透明、以证据为基础的调查方法，整合了相关人员的见解、监管审查和营运分析，以支持策略决策。

支撑这些发现的研究采用了多方面的方法，其核心是与关键相关人员的互动、临床证据综合以及营运分析。研究人员对临床医生、药剂师、支付方代表、采购负责人和患者权益倡导团体进行了结构化访谈，以了解他们对处方行为、依从性障碍和通路动态的实地观点。为了确保技术准确性和与当前实践的相关性，研究人员将这些定性研究结果与监管核准、指南修订和已发表的临床试验结果的系统性回顾进行了三角验证。

综合临床进展、服务需求和政策考量，为实际的暴露前预防（PrEP）决策提供指导。

总之，在治疗方法创新、不断演进的照护模式和不断变化的政策槓桿的推动下，PrEP领域正处于策略转折点。长效注射剂在提高依从性和维持率方面展现出令人瞩目的优势，但要充分发挥其潜力，需要重组给药途径并加强支付方的参与。同时，口服每日製剂对于广泛且分散的用药途径仍然至关重要，尤其是在药房和线上管道能够促进治疗启动和维持的地区。产品类型、给药途径、最终用户需求、通路和作用机制之间的相互作用，为生产者、支付方和医疗服务提供者建立了一个复杂但又可控的决策矩阵。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的PrEP药物市场

  • 品牌产品
    • 练习曲
    • 德斯科维
    • Truvada
  • 学名药

9. 按给药途径分類的PrEP药物市场

  • 注射
  • 口服

第十章 按分销管道分類的PrEP药物市场

  • 医院药房
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立药房

11. 按作用机转分類的PrEP药物市场

  • 整合酶链转移抑制剂
  • 核苷酸逆转录酶抑制剂

第十二章 各地区PrEP药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的PrEP药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国PrEP药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国PrEP药物市场

第十六章：中国PrEP药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Emcure Pharmaceuticals Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4F7A6D4FB6A2

The Drugs for PrEP Market was valued at USD 2.34 billion in 2025 and is projected to grow to USD 2.51 billion in 2026, with a CAGR of 8.26%, reaching USD 4.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.34 billion
Estimated Year [2026] USD 2.51 billion
Forecast Year [2032] USD 4.08 billion
CAGR (%) 8.26%

An orienting introduction to the dynamic PrEP prevention landscape, aligning clinical innovation with access and delivery realities

The prevention landscape for HIV pre-exposure prophylaxis (PrEP) is undergoing rapid transformation driven by therapeutic innovation, shifting care delivery models, and evolving payer and policy environments. Recent clinical advances have broadened the options available to individuals at risk, while health systems and community providers are adapting care pathways to improve uptake and persistence. Against this backdrop, stakeholders must reconcile the promise of long-acting modalities with the entrenched role of daily oral therapies, ensuring that clinical benefits translate into real-world access and equitable outcomes.

This introduction situates readers in the current environment, emphasizing the dual imperative of clinical efficacy and programmatic feasibility. It highlights how product characteristics, administration routes, and end-user needs intersect to shape decisions across manufacturers, payers, and providers. By framing the discussion around access, adherence, and delivery, the following sections explore the forces redefining PrEP strategy and offer a structured lens for evaluating investment, commercialization, and policy options. As the landscape evolves, organizations that align scientific innovation with pragmatic distribution and reimbursement tactics will be best positioned to expand prevention impact.

How clinical innovation, care delivery evolution, and payer policy are converging to drive transformative shifts across the PrEP ecosystem

The past several years have produced transformative shifts that are reshaping how PrEP is developed, delivered, and financed. A notable pivot toward long-acting injectable formulations has challenged the dominance of daily oral therapy by offering adherence advantages and novel service delivery opportunities. As evidence mounts for injectable agents in diverse populations, clinicians and health systems are reconsidering care models to support periodic clinic visits, injection administration, and monitoring, which in turn influences site-of-care economics and workforce planning. Concurrently, regulatory approvals and guideline updates have broadened indications and informed risk stratification, prompting payers to revisit formulary placement and prior authorization frameworks.

Beyond therapeutics, digital health and telemedicine have accelerated patient identification, initiation, and follow-up, bridging gaps created by geographic and social barriers. Community-based distribution and pharmacy engagement have expanded, enabling decentralized access while creating new partnerships between manufacturers and nontraditional channels. These converging trends underscore a shift from product-centric strategies to ecosystem-centric approaches, where success depends on coordinated clinical evidence generation, stakeholder alignment, and flexible distribution models that meet the needs of heterogeneous end users.

Assessing the cumulative operational and access implications of United States tariff shifts enacted in 2025 on PrEP supply chains and payer dynamics

The introduction of cumulative tariff changes in 2025 has introduced a new economic variable that affects supply chain design, procurement choices, and pricing strategies for PrEP products. Higher duties on imported active pharmaceutical ingredients, finished dosage forms, and packaging components increase landed input costs for both branded and generic producers, particularly when supply chains rely on cross-border sourcing of bulk materials. In response, manufacturers and contract manufacturers are evaluating nearshoring, vertical integration, and alternative sourcing strategies to protect margins and maintain supply reliability, while procurement teams reassess supplier diversification to mitigate concentration risk.

These trade measures also influence payer negotiations and formulary decision making. Where incremental cost pressures emerge, payers may tighten utilization management or accelerate value-based contracting conversations that tie reimbursement to adherence or clinical outcomes. Health systems that self-procure for hospital pharmacies and clinics face budgetary strain that can alter stocking practices and ordering cadence. At the same time, tariffs create an impetus for investment in domestic manufacturing capacity and bilateral trade agreements that could, over time, reduce exposure to external shocks. Overall, the policy environment introduced by 2025 tariffs highlights the need for strategic supply chain planning, transparent cost modeling, and collaborative approaches among manufacturers, payers, and health systems to preserve access to PrEP therapies.

Deep segmentation insight detailing how product type, administration route, end user, distribution channel, and mechanism of action jointly shape strategic choices

Segmenting the PrEP landscape reveals differentiated clinical, commercial, and operational implications that must guide strategy. Looking at product type, the landscape spans branded options-such as long-acting cabotegravir and established oral combinations-and generic formulations centered on TDF/FTC, each with distinct clinical profiles, patent trajectories, and pricing dynamics. These differences affect decisions about manufacturing scale, portfolio sequencing, and patient outreach, as branded long-acting agents may command premium positioning while generics drive broader accessibility.

When considering administration route, injectable therapies change the locus of care by requiring clinic-based encounters for long-acting dosing schedules, whereas daily oral regimens enable decentralized initiation and continuity through community and pharmacy channels. End user segmentation further refines targeting: prevention programs for men who have sex with men must integrate culturally competent outreach and rapid initiation pathways, while strategies for heterosexual adults and people who inject drugs require tailored adherence support, harm reduction alignment, and linkage to social services.

Distribution channel segmentation clarifies operational choices: hospital pharmacies play a critical role for clinic-administered injectables, online pharmacies expand reach for oral regimens, and retail pharmacies-both chain and independent-serve as essential access points for routine dispensing and patient counseling. Finally, mechanism of action distinctions-between integrase strand transfer inhibitors implemented as cabotegravir and nucleotide reverse transcriptase inhibitor options differentiated by TAF-based and TDF-based chemistries-inform clinical positioning, monitoring needs, and resistance stewardship. Together, these intersecting segmentations should drive differentiated commercialization, access planning, and evidence generation.

Regional lenses on access and adoption revealing how geographic variability in systems and financing drives differentiated PrEP deployment strategies

Regional dynamics significantly influence adoption pathways and operational priorities for PrEP interventions. In the Americas, a mature regulatory environment and established prevention programs coexist with persistent disparities in access; payer engagement and integrated care models drive uptake in urban centers, while community programs remain essential for reaching marginalized populations. Policy changes, procurement frameworks, and local manufacturing capacities further differentiate national responses across the region.

In Europe, Middle East & Africa, diversity in health system maturity and financing mechanisms produces heterogenous adoption patterns. High-income countries in Europe typically align guideline updates with systematic reimbursement pathways, enabling rapid incorporation of new modalities, whereas many countries in Africa and parts of the Middle East rely on donor programs, national guidelines, and task-shifting to scale preventive services. Supply chain resilience and affordability are central concerns, and partnerships with global procurement agencies often shape availability.

Across Asia-Pacific, a mix of large public programs, evolving private sector engagement, and variable regulatory timelines creates a nuanced landscape. Several countries are investing in domestic manufacturing and regulatory harmonization, which can shorten pathways for local supply, while others leverage private pharmacies and telehealth to expand access. Each region's structural characteristics-funding models, care delivery norms, and manufacturing footprints-should inform tailored strategies for product launch, distribution, and stakeholder engagement.

Key competitive and partnership insights highlighting how brand differentiation, generics, and distribution alliances determine real-world PrEP reach and uptake

Competitive dynamics in the PrEP arena reflect a balance between established brand owners, innovative modality entrants, and an expanding base of generic manufacturers. Brand owners that commercialize long-acting formulations have invested heavily in clinical development and provider education to support clinic-based administration, while companies with oral combination products have emphasized convenience, patient support programs, and broad pharmacy distribution. Generic manufacturers play a pivotal role in expanding affordability and access, especially in regions where procurement mechanisms prioritize cost containment and volume purchasing.

Partnerships between producers and distributors, plus collaborations with public health agencies and community organizations, increasingly determine real-world reach. Manufacturers that integrate demand generation with robust supply commitments, patient assistance frameworks, and clinician training gain traction across care settings. Additionally, innovators are exploring value partnerships with payers to align pricing with outcomes and adherence measures. Overall, competitive advantage accrues to organizations that combine clinical differentiation with pragmatic delivery models, resilient supply chains, and targeted stakeholder engagement across public and private channels.

Actionable recommendations for industry leaders to secure supply resilience, optimize delivery, and accelerate equitable access to PrEP innovations

Leaders across industry and policy spheres must translate insights into concrete actions to ensure sustained prevention impact. First, investing in diversified supply chains and dual sourcing for critical inputs will reduce exposure to trade policy shocks and preserve continuity of supply. Second, aligning product development with real-world delivery realities is essential; manufacturers should design clinical programs and packaging for ease of administration in both clinic and community settings, and develop adherence supports that reflect the needs of distinct end users.

Third, proactive payer engagement is critical to secure predictable access pathways. Early dialogue that links clinical value to outcomes and operational feasibility can streamline reimbursement and reduce initiation barriers. Fourth, distribution strategies need to be nuanced: integrating hospital pharmacies for injectable administration, leveraging online pharmacies for easier access to oral products, and partnering with chain and independent retail pharmacies for counseling and ongoing dispensing will broaden reach. Finally, public-private collaboration-spanning community organizations, health departments, and companies-can accelerate culturally competent outreach and retention, ensuring that scientific advances translate into equitable prevention outcomes.

Transparent, evidence-based research methodology that integrates stakeholder insights, regulatory review, and operational analysis to inform strategic decisions

The research underpinning these insights combined a multimodal approach centered on primary stakeholder engagement, clinical evidence synthesis, and operational analysis. We conducted structured interviews with clinicians, pharmacists, payer representatives, procurement officers, and patient advocates to capture frontline perspectives on prescribing behavior, adherence barriers, and channel dynamics. These qualitative inputs were triangulated with a systematic review of regulatory approvals, guideline revisions, and published clinical trial outcomes to ensure technical accuracy and relevance to current practice.

Operational dimensions relied on supply chain mapping, procurement process examination, and scenario analysis of policy developments such as tariff adjustments. Comparative case studies across different health systems informed regional differentiation and distribution channel assessment. Throughout, methodological rigor emphasized transparent data sourcing, cross-validation of interview findings with publicly available regulatory documents, and iterative expert review to refine interpretations. This blended methodology supports conclusions that are both evidence-based and pragmatic for decision makers seeking to translate insights into operational strategies.

Concluding synthesis that integrates clinical advances, delivery imperatives, and policy considerations to guide pragmatic PrEP decision making

In conclusion, the PrEP landscape is in a state of strategic transition driven by therapeutic innovation, evolving care models, and shifting policy levers. Long-acting injectables introduce promising adherence and retention advantages but require reconfigured delivery pathways and payer engagement to realize their full potential. Daily oral formulations remain indispensable for broad, decentralized access, especially where pharmacy and online channels facilitate initiation and persistence. The interplay of product type, administration route, end-user needs, distribution channels, and mechanism of action creates a complex but navigable decision matrix for manufacturers, payers, and providers.

External factors, including trade policy changes and regional system characteristics, add urgency to supply chain diversification and stakeholder collaboration. Organizations that align clinical differentiation with pragmatic distribution strategies, robust payer engagement, and culturally competent outreach will be best positioned to expand prevention coverage. Ultimately, converting scientific progress into population impact requires coordinated action across the commercial, clinical, and public health spheres to ensure that effective PrEP options reach those who can benefit most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for PrEP Market, by Product Type

  • 8.1. Branded
    • 8.1.1. Apretude
    • 8.1.2. Descovy
    • 8.1.3. Truvada
  • 8.2. Generic

9. Drugs for PrEP Market, by Administration Route

  • 9.1. Injectable
  • 9.2. Oral

10. Drugs for PrEP Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain Pharmacy
    • 10.3.2. Independent Pharmacy

11. Drugs for PrEP Market, by Mechanism Of Action

  • 11.1. Integrase Strand Transfer Inhibitors
  • 11.2. Nucleotide Reverse Transcriptase Inhibitors

12. Drugs for PrEP Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drugs for PrEP Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drugs for PrEP Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Drugs for PrEP Market

16. China Drugs for PrEP Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Astellas Pharma Inc.
  • 17.7. Aurobindo Pharma Limited
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol Myers Squibb Company
  • 17.10. Cipla Limited
  • 17.11. Emcure Pharmaceuticals Limited
  • 17.12. Gilead Sciences, Inc.
  • 17.13. GlaxoSmithKline plc
  • 17.14. Hetero Labs Limited
  • 17.15. Janssen Pharmaceuticals, Inc.
  • 17.16. Lupin Limited
  • 17.17. Macleods Pharmaceuticals Ltd.
  • 17.18. Merck KGaA
  • 17.19. Mylan N.V.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Sanofi SA
  • 17.23. Sun Pharmaceutical Industries Ltd.
  • 17.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR PREP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR PREP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR PREP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUGS FOR PREP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS DRUGS FOR PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. G7 DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. G7 DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. NATO DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. NATO DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)